A243070 Stock Overview
Huons Co., Ltd. ofrece soluciones médicas para la salud humana en Corea y a escala internacional.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
Huons Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩36,050.00 |
| 52 Week High | ₩49,500.00 |
| 52 Week Low | ₩28,900.00 |
| Beta | 0.41 |
| 1 Month Change | 4.34% |
| 3 Month Change | -6.85% |
| 1 Year Change | 11.09% |
| 3 Year Change | -33.24% |
| 5 Year Change | -28.81% |
| Change since IPO | -29.11% |
Recent News & Updates
Recent updates
Here's Why Huons (KOSDAQ:243070) Can Manage Its Debt Responsibly
Apr 20
We Think That There Are Issues Underlying Huons' (KOSDAQ:243070) Earnings
Mar 17Here's Why We Think Huons (KOSDAQ:243070) Is Well Worth Watching
Mar 12Is Huons Co., Ltd.'s (KOSDAQ:243070) Recent Performance Tethered To Its Attractive Financial Prospects?
Feb 21What Type Of Shareholders Own The Most Number of Huons Co., Ltd. (KOSDAQ:243070) Shares?
Feb 02Could Huons Co., Ltd. (KOSDAQ:243070) Have The Makings Of Another Dividend Aristocrat?
Jan 12Should You Buy Huons Co., Ltd. (KOSDAQ:243070) For Its Upcoming Dividend?
Dec 25
Update: Huons (KOSDAQ:243070) Stock Gained 28% In The Last Year
Dec 08Is Huons Co., Ltd.'s (KOSDAQ:243070) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Nov 18Shareholder Returns
| A243070 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 0.4% | -5.8% | -1.5% |
| 1Y | 11.1% | 10.1% | 7.5% |
Rentabilidad frente al sector: A243070 superó al sector KR Pharmaceuticals , que obtuvo un rendimiento del 10.1% el año pasado.
Rentabilidad vs. Mercado: A243070 superó al mercado KR, que obtuvo un rendimiento del 7.5% el año pasado.
Price Volatility
| A243070 volatility | |
|---|---|
| A243070 Average Weekly Movement | 4.5% |
| Pharmaceuticals Industry Average Movement | 4.7% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 12.0% |
| 10% least volatile stocks in KR Market | 2.4% |
Precio estable de las acciones: A243070 no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de A243070 (5%) se ha mantenido estable durante el año pasado.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1965 | 912 | n/a | https://www.huons.com |
Huons Co., Ltd. ofrece soluciones médicas para la salud humana en Corea y a escala internacional. La empresa ofrece medicamentos orales en forma sólida, como productos para el sistema circulatorio, metabólicos, antipiréticos, analgésicos, antiinflamatorios, para el sistema musculoesquelético, para el sistema digestivo, antihistamínicos, para el sistema respiratorio, antibióticos, para el bienestar, para el sistema urogenital y otros productos quimioterapéuticos; y productos inyectables, como anestésicos, antipiréticos, analgésicos, antiinflamatorios, relajantes del músculo esquelético, antiespasmódicos, antihistamínicos, del sistema circulatorio, del sistema respiratorio, hormonas adrenocorticales, enzimas, minerales, disolventes, calcio, hemostáticos, antídotos, antibióticos, metabólicos, ácido hialurónico, bienestar, anticoagulantes y otros productos del sistema celular tisular. También ofrece colirios y productos biológicos, así como dispositivos médicos.
Huons Co., Ltd. Fundamentals Summary
| A243070 fundamental statistics | |
|---|---|
| Market cap | ₩428.04b |
| Earnings (TTM) | ₩50.47b |
| Revenue (TTM) | ₩552.01b |
8.5x
P/E Ratio0.8x
P/S RatioIs A243070 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A243070 income statement (TTM) | |
|---|---|
| Revenue | ₩552.01b |
| Cost of Revenue | ₩266.07b |
| Gross Profit | ₩285.94b |
| Other Expenses | ₩235.47b |
| Earnings | ₩50.47b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.25k |
| Gross Margin | 51.80% |
| Net Profit Margin | 9.14% |
| Debt/Equity Ratio | 34.7% |
How did A243070 perform over the long term?
See historical performance and comparison